AU2003299652A1 - Methods for treating diabetes - Google Patents

Methods for treating diabetes

Info

Publication number
AU2003299652A1
AU2003299652A1 AU2003299652A AU2003299652A AU2003299652A1 AU 2003299652 A1 AU2003299652 A1 AU 2003299652A1 AU 2003299652 A AU2003299652 A AU 2003299652A AU 2003299652 A AU2003299652 A AU 2003299652A AU 2003299652 A1 AU2003299652 A1 AU 2003299652A1
Authority
AU
Australia
Prior art keywords
methods
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299652A
Other languages
English (en)
Other versions
AU2003299652A8 (en
Inventor
Satyanarayana Medicherla
Andrew A. Protter
George F. Schreiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU2003299652A8 publication Critical patent/AU2003299652A8/xx
Publication of AU2003299652A1 publication Critical patent/AU2003299652A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003299652A 2002-12-06 2003-12-05 Methods for treating diabetes Abandoned AU2003299652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43124102P 2002-12-06 2002-12-06
US60/431,241 2002-12-06
PCT/US2003/040140 WO2004053107A2 (en) 2002-12-06 2003-12-05 Methods for treating diabetes

Publications (2)

Publication Number Publication Date
AU2003299652A8 AU2003299652A8 (en) 2004-06-30
AU2003299652A1 true AU2003299652A1 (en) 2004-06-30

Family

ID=32507688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299652A Abandoned AU2003299652A1 (en) 2002-12-06 2003-12-05 Methods for treating diabetes

Country Status (6)

Country Link
US (1) US20040171659A1 (enExample)
EP (1) EP1583535A4 (enExample)
JP (1) JP2006510654A (enExample)
AU (1) AU2003299652A1 (enExample)
CA (1) CA2511763A1 (enExample)
WO (1) WO2004053107A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7765004B2 (en) * 2005-04-28 2010-07-27 Cardiac Pacemakers, Inc. Methods and systems for managing fusion and noise in cardiac pacing response classification
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
CA2857374A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4619652A (en) * 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2000506532A (ja) * 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
AU772295B2 (en) * 1999-05-21 2004-04-22 Scios Inc. Indole-type derivatives as inhibitors of p38 kinase

Also Published As

Publication number Publication date
WO2004053107A2 (en) 2004-06-24
CA2511763A1 (en) 2004-06-24
EP1583535A4 (en) 2008-03-19
US20040171659A1 (en) 2004-09-02
EP1583535A2 (en) 2005-10-12
AU2003299652A8 (en) 2004-06-30
JP2006510654A (ja) 2006-03-30
WO2004053107A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2003297762A1 (en) Methods for treating essential tremor
AU2001231104A1 (en) Methods for treating diabetes
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2002951841A0 (en) Apparatus
AU2002232187A1 (en) Authenticating method
AU2003211296A1 (en) Hairdyeing apparatus
AUPS160602A0 (en) Therapeutic method
IL165242A0 (en) Treatment for diabetes
AU2003210777A1 (en) Improved desulfurization process
AU2003258070A1 (en) Electrodionization method
AU2003278355A1 (en) Process
AU2003222120A1 (en) Oxon process
AU2003222022A1 (en) Methods for treating deodorizer distillate
AUPS091102A0 (en) Method for treating carbonaceous materials
AU2003264487A1 (en) Substance-atomizing apparatus
AU2003299652A1 (en) Methods for treating diabetes
AU2003219857A1 (en) Process for treating disease
WO2004071432A3 (en) Method for treating hypothyroidism
AU2003253813A1 (en) Method for colpoplasty
AU2003214171A1 (en) Method for treating diabetic ulcers
AU2003211685A1 (en) Switch-charging apparatus
AU2003293672A1 (en) Secretion-collecting apparatus
AU2003274309A1 (en) Apparatus
AU2003263197A1 (en) Process
AU2003278535A1 (en) Histoscreen method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase